US 12,404,315 B2
Protease-activating CD45-gate CAR
Shanshan Lang, San Mateo, CA (US); Thomas John Van Blarcom, Oakland, CA (US); Michael Thomas Bethune, Castro Valley, CA (US); Siler Panowski, Berkeley, CA (US); Nguyen Tan, Berkeley, CA (US); Yi Zhang, Foster City, CA (US); Barbra Johnson Sasu, San Francisco, CA (US); and Zhe Li, Burlingame, CA (US)
Assigned to Allogene Therapeutics, Inc., South San Francisco, CA (US); and Pfizer Inc., New York, NY (US)
Filed by ALLOGENE THERAPEUTICS, INC., South San Francisco, CA (US); and PFIZER INC., New York, NY (US)
Filed on Dec. 21, 2021, as Appl. No. 17/557,654.
Claims priority of provisional application 63/289,984, filed on Dec. 15, 2021.
Claims priority of provisional application 63/128,667, filed on Dec. 21, 2020.
Prior Publication US 2022/0227832 A1, Jul. 21, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 19/00 (2006.01); C12N 5/078 (2010.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01); C12N 15/79 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/4224 (2025.01); A61K 40/4252 (2025.01); A61K 40/4257 (2025.01); C07K 14/70521 (2013.01); C07K 14/70596 (2013.01); C07K 16/28 (2013.01); C07K 16/289 (2013.01); C07K 19/00 (2013.01); C12N 5/0634 (2013.01); C12N 5/0636 (2013.01); C12N 5/10 (2013.01); C12N 15/79 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/49 (2023.05); A61K 2239/55 (2023.05); A61K 2239/59 (2023.05); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/569 (2013.01); C07K 2319/01 (2013.01); C07K 2319/31 (2013.01); C07K 2319/50 (2013.01)] 35 Claims
 
1. A protease-activating CD45-gate chimeric antigen receptor (CD45-gate CAR) comprising an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain comprises:
a CD45 recruiting domain comprising an anti-CD45 antibody, or an antigen binding fragment thereof,
an antigen binding domain, and
a linker comprising one or more protease cleavage sites that is cleavable by at least one protease.